相关实验视频

Updated: May 8, 2025

Full- versus Sub-Regional Quantification of Amyloid-Beta Load on Mouse Brain Sections

Full- versus Sub-Regional Quantification of Amyloid-Beta Load on Mouse Brain Sections

Published on: May 19, 2022

针对早期症状性阿尔茨海默氏病的抗Aβ抗体治疗的实用脑部MRI指南

Shingo Kakeda¹, Yukio Miki², Kohsuke Kudo³

¹Department of Radiology, Hirosaki University Graduate School of Medicine, Hirosaki, Aomori, 036-8562, Japan. kakeda@hirosaki-u.ac.jp.

Japanese journal of radiology

|April 23, 2025

概括

这些指导方针支持磁共振成像 (MRI) 诊断与粉样蛋白相关的成像异常 (ARIA) 在接受抗粉样蛋白β (Aβ) 抗体治疗的患者中,确保安全有效的护理.

科学领域:

神经辐射学神经辐射学
医疗成像医学成像
药理学药理学是指药理学的学科.

背景情况:

抗粉样β (Aβ) 抗体疗法是神经疾病的新兴治疗方法.
准确的诊断和治疗相关副作用的管理是至关重要的.
磁共振成像 (MRI) 在监测治疗反应和不良事件方面发挥着关键作用.

研究的目的:

为在接受抗粉胺β (Aβ) 抗体治疗的患者中建立MRI诊断指南.
支持临床医生诊断和管理与粉样蛋白相关的成像异常 (ARIA).
确保治疗资格不受诊断能力的限制.

主要方法:

由日本领先的放射学和医学成像学会合作开发.
对现有文献和临床试验数据进行全面审查.
纳入已建立的国家指导方针,以优化医疗成像的使用.

主要成果:

医生需要大脑MRI解释的专业知识和ARIA的知识.
设施必须符合特定标准,包括遵守"最佳使用促进指南".
建议对ARIA,MRI,抗Aβ疗法和治疗后诊断进行培训.

结论:

指南有助于准确的ARIA诊断和管理.
确保安全使用抗Aβ药物.
为MRI设施提供框架,包括人员和系统要求.

关键词:

阿尔茨海默氏症的疾病是阿尔茨海默氏症.与粉样蛋白相关的成像异常抗粉胺β抗体治疗方法脑子脑子脑子脑子准则准则准则准则磁共振成像技术磁共振成像技术

更多相关视频

Detecting Amyloid-β Accumulation via Immunofluorescent Staining in a Mouse Model of Alzheimer's Disease

Detecting Amyloid-β Accumulation via Immunofluorescent Staining in a Mouse Model of Alzheimer's Disease

Published on: April 19, 2021

Intracerebroventricular Injection of Amyloid-β Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits

Intracerebroventricular Injection of Amyloid-β Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits

Published on: March 16, 2016

相关概念视频

Alzheimer's Disease: Treatment

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...

Alzheimer's Disease: Overview

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...